Prominent players in the diabetic neuropathy market are directing their efforts towards developing novel molecules and drugs, and are procuring approvals from concerned regulatory bodies to distribute products on a wide scale.
ROCKVILLE, MD / ACCESSWIRE / September 9, 2020 / The diabetic neuropathy market is projected to grow at a healthy CAGR of 5.6% in terms of value through the period of forecasting between 2020 and 2025. The growth of the market is essentially attributed to the rising prevalence of diabetes worldwide, coupled with increasing approvals of novel drugs for treating diabetic neuropathic pain. The market is expected to mitigate the risk posed by COVID-19, as demand for essential drugs remains persistent and players expand the functional capacity.
“With over 420 Mn people across the world suffering diabetes, there is a continual need for effective diabetic treatment. On this premise, the diabetic neuropathy market is expected to register robust growth worldwide, especially in the Asia Pacific, where the majority of the diabetic population is concentrated,” says the Fact.MR report.
Request a sample of the report to gain more market insights at
https://www.factmr.com/connectus/sample?flag=S&rep_id=4698
Diabetic Neuropathy Market – Key Takeaways
Diabetic Neuropathy Market – Driving Factors
Diabetic Neuropathy Market – Constraints
Anticipated Market Impact by Coronavirus Outbreak
The growth of the market is expected to remain undisrupted through the pandemic period. With diabetes patients being a higher risk group of COVID-19, patients are seeking drugs as a measure to prevent complications in case they contract the infection. On this premise, market players are upscaling their production capacity to cater to the growing demand for essential pharmaceuticals. Although operations are experiencing delays due to travel restrictions, the continual demand for drugs is outweighing the challenges arisen due to the pandemic.
Explore the global diabetic neuropathy market with 116 figures, 96 data tables, along with the table of contents of the report. You can also find detailed segmentation on https://www.factmr.com/report/4698/diabetic-neuropathy-market
Competition Landscape
The key players operating in the diabetic neuropathy market include Johnson & Johnson (Janssen Global Services, LLC), Boehringer Ingelheim GmbH, NeuroMetrix, Inc., Eli Lilly and Company, GlaxoSmithKline Plc., Lupin Limited, Astellas Pharma Inc., Pfizer, Inc., Glenmark Pharmaceuticals Ltd., Arbor Pharmaceuticals, LLC, and Depomed, Inc. Market players, especially new entrants, are continually focusing on developing new drugs and studying new formulations to gain a competitive edge. For instance, Glenmark Pharmaceuticals Ltd., successfully out-licensed seven novel molecules to leading players such as Merck KGaA and remains the only company to execute multiple deals on novel molecules.
More on the Report
The FACT.MR’s market research report provides in-depth insights into the diabetic neuropathy market. The market is scrutinized based on the disorder (Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy, and Focal Neuropathy), treatment (Drugs, Radiotherapy, and Physiotherapy), and distribution channel (Hospitals, Clinics, Retail Pharmacy, and Online Pharmacy) (North America, Europe, East Asia, Asia Pacific, Latin America, and Middle East & Africa (MEA).
Explore Wide-ranging Coverage of FACT.MR’s Healthcare Landscape
Neuro Ablation Devices Market: Find insights on the neuro ablation devices market with analysis of segments, statistics, influencers, market players, and business strategies adopted over a 10-year forecast period.
Neuralgia Treatment Market: FACT.MR’s report on the neuralgia treatment market offers insights on the market during 2018-2028, including restraints, revenue sources, market leaders, and market strategies.
Glaucoma Therapeutics Market: Read an analysis of the glaucoma therapeutics market with insights on growth factors, opportunities, restraints, regional market forecast, regulatory policies, and strengths of market leaders.
About Fact.MR
Fact.MR is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. Fact.MR is headquartered in Dublin, and has offices in Dubai. FACT.MR’s latest market research reports industry analysis help businesses navigate challenges and take critical decisions with confidence and clarity amidst breakneck competition.
Contact:
Fact.MR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/
PR- https://www.factmr.com/media-release/1608/diabetic-neuropathy-market-trends
SOURCE: FactMR
View source version on accesswire.com:
https://www.accesswire.com/605361/Diabetic-Neuropathy-Market-to-Expand-at-CAGR-of-56-through-2025-Growth-Trajectory-Remains-Unhinged-During-COVID-19-Pandemic-Opines-FactMRs-New-Study
Presenting a New Innovation in the Field of Spinal Rehabilitation at Physiowell DubaiDUBAI, ARAB EMIRATES…
SINGAPORE, June 23, 2024 /PRNewswire/ -- Singapore-headquartered Juniper Biologics Pte Ltd (Juniper), a leading healthcare…
FRONTIER2 data presented at ISTH 2024 showed that up to 95% of people, who had…
Pemvidutide elicited significant weight loss and decreases in pro-inflammatory serum lipids associated with atherogenesis and…
TAIPEI, June 22, 2024 /PRNewswire/ -- The prestigious 2024 Tang Prize Laureates have been announced,…
Afrezza® Afrezza® (insulin human) Inhalation Powder. Study proves inhaled insulin is as effective as usual…